Research — page 4

A 2026 cohort of 300,000+ patients found cannabis use disorder linked to 3.87x higher lung cancer risk. The data, the caveats, and what it means for users.

A 2026 scoping review of 28 RCTs across 12 DSM-5 conditions. Where cannabinoids show benefit, where evidence is thin, and what we still don't know.

Depressed patients widely use cannabis for sleep — and the science is nuanced. Real perceived benefit, real architecture concerns. What 2026 research shows.

A 2026 longitudinal study of 11,000+ youth shows THC exposure tracks with measurable brain trajectory changes — while CBD does not. The data parents need.

The first randomized trial of cannabis for acute migraine: vaporized THC+CBD flower beat placebo for pain freedom at 2 hours. What the science actually says.

Cannabis flavonoids — especially cannflavin A — match ibuprofen for anti-inflammatory potency. The third bioactive category most consumers have never heard of.

The UK Medical Cannabis Registry tracked 698 patients prescribed cannabis for depression. Mood, sleep, and anxiety all improved — with one important caveat.

Cannabis terpenes relieve pain via adenosine A2A receptors, not CB1/CB2 — with morphine-comparable analgesia. Why this rewrites the pain conversation.

A 2026 study: cannabis works better for chronic pain when it ALSO improves sleep, stress, and mood. Why multi-system effects matter — and how to use them.

A 2026 study found CBD reverses nicotine-induced glymphatic system damage in animal models. The neuroscience and the practical takeaway for vapers.

CBD has poor bioavailability — only 6-19% reaches your bloodstream. New nanoparticle research could change that, opening doors to stroke therapy.

A 2026 compliance study found 56% of hemp-derived THC retailers sold to underage-appearing buyers. What this means for parents, consumers, and the industry.

Tetraploid cannabis plants carry double the chromosomes of normal plants. Here's what polyploid breeding actually does to potency, terpenes, and your flower.

A 2026 cohort of 954 patients found alcohol roughly doubles brain aneurysm rupture risk while cannabis showed no significant link. The data, with caveats.

A 2026 Lancet Psychiatry meta-analysis pooled 54 RCTs of cannabinoid mental health treatments. Signals, null results, and the GRADE-rated honest verdict.

After 50 years of male-dominated cannabis use, women now consume more in key segments. The data, the products, and what's driving the gender reversal.

Your brain makes its own cannabinoid called 2-AG. New research shows it controls dopamine-driven decisions — and why this matters for cannabis users.

A Feb 2026 Addiction meta-analysis links cannabis ad exposure to higher odds of use, with the strongest signal for digital and social-media ads.

What the research actually shows about cannabis for menopause symptoms—sleep, mood, hot flashes, and joint pain—and the limits of current evidence.

A 2026 NHANES analysis of 5,827 middle-aged adults links frequent cannabis use to lower Klotho, a biological-aging biomarker. A sober, hedged breakdown.

Gelato sits at #2 on our popularity leaderboard. A data-driven look at terpenes, Cookies-era lineage, and why its descendants dominate modern cannabis.

What does the latest research say about cannabis and bipolar disorder? A science-based look at real risks, drug interactions, and harm reduction.

Explore what research says about cannabis and OCD, from endocannabinoid science to practical considerations for managing obsessive-compulsive symptoms.

Discover eucalyptol (1,8-cineole): cannabis's rare cooling terpene with real respiratory and anti-inflammatory research behind it.